Elder Pharmaceuticals is launching Phytomega, a unique combination of Omega-3 fatty acids and phytosterols
Elder Pharmaceuticals, a India-based globally focused drug maker, is launching Phytomega, a unique combination of Omega-3 fatty acids and phytosterols, which has been proven to reduce lipid levels in the body. This product has been licensed to Elder by an Israeli pharma company Enzymotec.
Clinical trials have documented the efficacy of Phytomega in reducing LDL as well as triglycerides (two types of lipids) as compared to statins (products used to lower lipids) that reduce either one of them. Since derived from natural sources, the product is devoid of side effects that would be associated with statins.
Phytomega would be promoted to all the leading physicians, cardiologists and general practitioners across the country. The total market size for this product is around $126 million, of which the primary market of Omega-3 fatty acids is worth $25 million. The major players in this segment are Wockhardt, Nicholas Piramal and GSK.